MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2023 International Congress

    Asian LRRK2 variants do not increase Likelihood Ratios derived from MDS prodromal Parkinson’s Disease criteria in a community population

    R. Chen, C. Chai, N. Chia, S. Ng, E. Ng, E. Tan, Z. Xu, L. Tan (Singapore, Singapore)

    Objective: To determine if the presence of the Asian LRRK2 risk variants (G238R, S1647T, R1628P) confers an increased risk in developing PD in a Singaporean…
  • 2023 International Congress

    Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson’s disease

    K. Basharova, A. Bezrukova, A. Izyumchenko, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: The aim was to evaluate the effectiveness of leucine-rich repeat kinase 2 (LRRK2) kinase activity inhibition in restoring transport of the enzyme glucocerebrosidase (GCase),…
  • 2023 International Congress

    Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort

    S. Lettenberger, P. Auinger, R. Wilson, E. Hartman, M. Pawlik, M. Khokhar, E. Dorsey, B. Valdovinos, S. Sharma, R. Holloway, C. Tanner, R. Alcalay, R. Schneider (Rochester, USA)

    Objective: To examine change in clinical characteristics in LRRK2 G2019S carriers with Parkinson’s disease (PD) and without PD (non-manifest carriers) enrolled in Virtual Assessment of…
  • 2023 International Congress

    LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing

    J. Meredith Jr, K. Kelly, V. Guss, A. Desantis, L. Kimmel, S. Soletsky, J. Pizzano, G. Cadelina, J. Chavez, S. Sparks, A. Cacace (New Haven, USA)

    Objective: Report on the non-clinical in vivo pharmacokinetic and pharmacodynamic biomarker response to PROteolysis TArgeting Chimera (PROTAC®) molecules designed to induce degradation of leucine rich…
  • 2023 International Congress

    The natural history of Parkinson’s disease in LRRK2 G2019S carriers

    M. Kmiecik, D. Coker, K. Heilbron, S. Aslibekyan, J. Shelton, P. Cannon, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To document differences between the evolution of self-reported symptoms and prodromal markers in LRRK2 G2019S carriers and non-carriers with and without Parkinson’s Disease (PD).…
  • 2023 International Congress

    Genetic profile of early-onset Parkinson’s Disease patients at a movement disorders center in Brazil

    M. Costa, A. Pessoa-Neto, F. Sarmento, G. Lima, C. Silva, L. Barcelos, P. Aguiar, S. Azevedo, V. Borges, H. Ferraz (São Paulo, Brazil)

    Objective: This study aimed to identify the genetic landscape of early-onset Parkinson’s Disease (EOPD) in a cohort from a referral center in Brazil. Background: Parkinson’s…
  • 2023 International Congress

    monogenic parkinsonism in latin america: systematic review and meta-analysis

    P. Saffie-Awad, D. Texeira, P. Chana-Cuevas, A. Schumacher-Schuh (Santiago, Chile)

    Objective: This study aims to assess the frequency, distribution and the minimum prevalence of monogenic Parkinsonism in Latin America (LA) Background: The prevalence of monogenic…
  • 2023 International Congress

    Oculomotor changes in the premotor stage of LRRK2- G2019S associated Parkinson’s disease.

    M. Rivera Sánchez, C. Lage Martínez, A. Sánchez Rodríguez, M. Sierra Peña, I. González Aramburu, L. Manrique Arregui, MV. Sánchez Peláez, C. García Cena, A. Calvo Córdoba, J. Madera Fernández, J. Martín Arroyo, J. Infante Ceberio (Santander, Spain)

    Objective: To analyse oculomotor differences among idiopathic PD patients (iPD), LRRK2-G2019S PD patients (LRRK2-G2019S PD), asymptomatic carriers of LRRK2-G2019S mutation (AsG2019S), and controls, evaluated by…
  • 2023 International Congress

    LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway

    JY. Liu, KJ. He, JB. Zhang, F. Wang, CF. Liu (Suzhou, China)

    Objective: Analyzing the mechanism of inflammatory response induced by oligomeric α-synuclein (O-αS) in LRRK2 G2019S mutation astrocytes to provide new targets and ideas for the…
  • 2023 International Congress

    Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC® degrader molecules as potential disease modifying therapeutics for Parkinson’s disease

    K. Kelly, J. Meredith, L. Kimmel, S. Sparks, A. Desantis, D. Bryce, R. Wilson, J. Corradi, S. Keenan, G. Cadelina, J. Pizzano, A. Cacace (New Haven, USA)

    Objective: Report on the pharmacological characteristics of small molecule PROteolysis TArgeting Chimera (PROTAC) molecules designed to induce degradation of leucine rich repeat kinase 2 (LRRK2)…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Effect of marijuana on Essential Tremor: A case report
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Insulin dependent diabetes and hand tremor
      • Patients with Essential Tremor Live Longer than their Relatives
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley